MindWalk Holdings Corp. Files 6-K, Reports Press Release

Ticker: HYFT · Form: 6-K · Filed: Sep 10, 2025 · CIK: 1715925

Sentiment: neutral

Topics: filing, press-release, company-update

TL;DR

MindWalk Holdings (fka ImmunoPrecise Antibodies) filed a 6-K on Sept 10, 2025, with a press release attached.

AI Summary

MindWalk Holdings Corp. (formerly ImmunoPrecise Antibodies Ltd.) filed a Form 6-K on September 10, 2025, reporting a press release dated September 10, 2025. The filing indicates the company is a foreign private issuer and will file annual reports under Form 20-F. The company's principal executive office is located in Austin, Texas.

Why It Matters

This filing provides an update from MindWalk Holdings Corp., formerly ImmunoPrecise Antibodies Ltd., which may contain important operational or strategic information for investors.

Risk Assessment

Risk Level: low — This is a routine filing (6-K) that primarily serves to attach a press release, without disclosing significant new financial or operational risks.

Key Players & Entities

FAQ

What is the primary purpose of this 6-K filing?

The primary purpose of this 6-K filing is to report a press release dated September 10, 2025, from MindWalk Holdings Corp.

What was the former name of MindWalk Holdings Corp.?

The former name of MindWalk Holdings Corp. was ImmunoPrecise Antibodies Ltd., with a date of name change on August 30, 2017.

Where is MindWalk Holdings Corp.'s principal executive office located?

MindWalk Holdings Corp.'s principal executive office is located at Industrious, 823 Congress Ave, Suite 300, Austin, Texas 78701.

Does MindWalk Holdings Corp. file annual reports under Form 20-F or 40-F?

MindWalk Holdings Corp. indicates it files or will file annual reports under cover of Form 20-F.

What is the SIC code for MindWalk Holdings Corp.?

The Standard Industrial Classification (SIC) code for MindWalk Holdings Corp. is 2834, which corresponds to Pharmaceutical Preparations.

Filing Stats: 144 words · 1 min read · ~1 pages · Grade level 11.4 · Accepted 2025-09-10 09:41:57

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. IMMUNOPRECISE ANTIBODIES LTD. Date: September 10, 2025 By: /s/ Jennifer Bath Name: Jennifer Bath Title: President and Chief Executive Officer

View Full Filing

View this 6-K filing on SEC EDGAR

View on Read The Filing